Back to results
US 11,090,290 B2Granted
Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy
AssigneeMonopar Therapeutics Inc.
InventorsBérangère Vasseur-Demarcy, Pierre Attali
Life of this patent
Estimating the term…
Abstract
The present invention pertains to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and Clonidine and/or Clonidine derivatives as a sole active ingredient for use in the prevention of skin injury resulting from radiotherapy by transmucocal administration.
Claims8
A method for reducing the risk of radiodermatitis in a subject undergoing radiotherapy, comprising
- administering by transmucosal route an effective amount of a clonidine and/or clonidine derivative selected from the group consisting of:
- clonidine, p-aminoclonidine, p-diethylamino clonidine, p-ethylamino clonidine, p-acetamido clonidine, p-bromoacetamido clonidine, p-N-chloroethyl-N-methylamino clonidine, p-N-β-chloroethyl-N-methylaminomethyl clonidine, 3,5-dichloro-4-(imidazolidin-2-ylideneamino)benzyl alcohol, 3,5-dichloro-4-(I,3-diisobutyryl imidazolidin-2-ylideneamino)benzyl isobutyrate, ethyl 3,5-dichloro-4-(I-isobutyrylimidazolidin-2-ylideneamino)benzoate, and mixtures thereof, to the subject,
- wherein the clonidine or clonidine derivative is administered on a daily basis 1 to 8 days before the subject begins the radiotherapy.
Dependencies are inferred from the claim text.